logo-loader
viewZynerba Pharmaceuticals

Zynerba Pharmaceuticals well-funded for its CBD clinical trials into 2021

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) CEO Armando Anido tells Proactive Investors the Pennsylvania-based biotech has $59.8 million to fund clinical trials for its cannabis-derived treatments 'beyond major milestones' into 2021.

Zynerba is on track to report top-line results from tests of its Zygel, a CBD gel treatment for children and adolescents with Fragile X syndrome. Anido says the results are expected by the second half of 2019.

Quick facts: Zynerba Pharmaceuticals

Price: 4.92 USD

NASDAQ:ZYNE
Market: NASDAQ
Market Cap: $114.13 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zynerba Pharmaceuticals named herein, including the promotion by the Company of Zynerba Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Chaarat Gold's Dusty Nicol talks increase to reserves at Tulkubash

Chaarat Gold Holdings Ltd's (LON:CGH) Dusty Nicol caught up with Proactive London's Andrew Scott to talk through the increase in reserves that's been announced for its Tulkubash project in Kyrgyz Republic. It follows last year's 20,000 metre drilling programme. Proven & probable...

1 day, 13 hours ago

2 min read